Silicon Laboratories stock barely flinched after earnings, slipping only 0.05% to about US$218. Yet the real story sits far beyond today’s flat tape. The company is still loss making, with trailing twelve month net income from continuing operations in the red and basic earnings per share also negative. At the same time, Silicon Laboratories trades on a rich valuation, with a P/S multiple above both peer and broader semiconductor industry averages. The rest of this report examines whether that premium aligns with the company’s revenue profile and its balance of risk and potential reward.
Love Silicon Laboratories’ premium revenue profile but concerned about paying up for a loss making stock? Benchmark it against a curated list of solid operators by scanning our list of solid balance sheet and fundamentals stocks (49 results).
Q2 2026 Earnings Summary
- Revenue, Q2 2026 vs. Q2 2025: US$213.5 million vs. US$192.845 million (change reflects higher quarterly revenue year on year)
- Net Loss, Q2 2026 vs. Q2 2025: US$15.897 million loss vs. US$21.817 million loss (quarterly loss narrowed year on year)
- Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.48 per share vs. loss of US$0.67 per share (quarterly per share loss improved year on year)
- Trailing Twelve Month Revenue, Q2 2026 vs. Q2 2025: US$820.55 million vs. US$703.203 million (revenue higher on a trailing twelve month basis)
Prefer clean charts over scrolling through another wall of earnings tables and footnotes? See the full visual financial picture for Silicon Laboratories, including how the current valuation compares, in our company report for Silicon Laboratories.
Silicon Laboratories bull case leans on IoT proof points
Bulls argue that Silicon Laboratories is building a higher quality IoT mix, with industrial, smart home and medical design wins turning into durable growth and better profitability. Q2 results lend some support. Revenue of US$213.5 million and higher trailing twelve month revenue of US$820.55 million indicate that end markets like smart grid and building automation are contributing meaningfully, consistent with the 500k plus Wi SUN (Wireless Smart Utility Network) modules shipped into India’s smart meter rollout. The record medical revenue flagged around Q2 also lines up with the thesis that medical IoT, including continuous glucose monitoring, is starting to matter. Losses are still present, but the quarterly net loss and basic EPS loss both narrowed compared with Q2 2025, which points to some operating leverage as these newer, higher value programs scale.
Bear case on losses and execution risk not cleared
Bears focus on two claims. Losses could persist if new platforms do not convert to high volume programs, and the stock could be vulnerable if margins or mix slip. Q2 does not fully remove those worries. Silicon Laboratories still reported a quarterly loss of US$15.897 million and a trailing twelve month net loss, so the business is not yet self funding. The narrowing loss versus Q2 2025 challenges the idea of deteriorating profitability, but the dependence on future ramps like the BG2B Bluetooth SoC, Philips Hue Matter integration and medical programs keeps execution risk very real. The company has also suspended guidance because of the pending Texas Instruments acquisition, which limits visibility just as investors are weighing whether recent IoT wins are repeatable at scale.
Reveal where the surface looks calm, but the models for Silicon Laboratories start to disagree. Access the multi year revenue and earnings analyst estimates for Silicon Laboratories.Stay Ahead With Simply Wall St
If the mix of losses and premium valuation around Silicon Laboratories has your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on price versus fair value and wait for a setup that suits you. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key developments that matter for your holdings. For a broader view, lean on the Community to see how other investors are thinking about the same risks and opportunities. This way you can spot hidden catalysts or early warning signs sooner and stay ahead of the market.
Seeking Alternatives Beyond Silicon Laboratories?
Fresh stock stories are breaking out while others drop off the radar. Use these curated ideas before the crowd catches on and the best entry points fly. Act now.
- Scan for resilient compounders that balance momentum with downside protection by checking the curated 85 resilient stocks with low risk scores while prices and risk profiles still look aligned.
- Ride potential AI momentum with companies already generating cash, not just burning it, by reviewing the hand picked list in the 70 profitable AI stocks that aren't just burning cash.
- Position ahead of possible infrastructure breakouts by assessing power grid technology leaders on the selectively filtered 36 power grid technology and infrastructure stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com